Compare AEYE & MOLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AEYE | MOLN |
|---|---|---|
| Founded | 2005 | 2004 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | |
| Sector | Technology | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 170.9M | 157.8M |
| IPO Year | N/A | 2021 |
| Metric | AEYE | MOLN |
|---|---|---|
| Price | $12.30 | $4.12 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 3 | 1 |
| Target Price | ★ $22.00 | $4.00 |
| AVG Volume (30 Days) | ★ 109.5K | 10.9K |
| Earning Date | 11-04-2025 | 10-30-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $39,540,000.00 | N/A |
| Revenue This Year | $17.16 | N/A |
| Revenue Next Year | $14.79 | $1,000.00 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 18.57 | N/A |
| 52 Week Low | $8.91 | $3.36 |
| 52 Week High | $28.50 | $5.99 |
| Indicator | AEYE | MOLN |
|---|---|---|
| Relative Strength Index (RSI) | 44.56 | 52.30 |
| Support Level | $11.04 | $3.99 |
| Resistance Level | $12.92 | $4.11 |
| Average True Range (ATR) | 0.73 | 0.26 |
| MACD | 0.01 | -0.03 |
| Stochastic Oscillator | 43.88 | 28.59 |
AudioEye Inc is a software solution provider delivering immediate ADA and WCAG accessibility compliance at scale. Through patented technology, subject matter expertise and proprietary processes, it is eradicating all barriers to digital accessibility, helping creators get accessible and supporting them with ongoing advisory and automated upkeep. Trusted by the ADP, Tommy Hilfiger, A360 Media, Samsung, Landry's and others. It helps everyone identify and resolve issues of accessibility and enhance user experiences, automating digital accessibility for the widest audiences.
Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company's product pipeline is organized principally through three areas: Ophthalmology, including the creation of therapies for retinal diseases like wet age-related macular degeneration and diabetic macular edema; the Oncology pipeline comprises DARPin candidates with novel modes of action, including multi-DARPin compounds; and Immuno-oncology for anticancer treatment.